Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The SURMOUNT-4 trial demonstrated that patients who discontinued tirzepatide experienced gradual weight regain, though the rate and extent varied considerably among individuals
M., Mitrovich, Q
P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with obesity or overweight and knee osteoarthritis, potential efficacy and tolerability of retatrutide, and the timeline for future readouts, presentations, and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
SURMOUNT-1 subgroup data from 2,542 women showed tirzepatide produced ~23% body weight reduction in peri/postmenopausal women vs 3% on placebo
This sophisticated delivery mechanism transforms a notoriously poorly absorbed nutrient into a highly bioavailable therapeutic tool, capable of significantly elevating systemic bodily stores of this crucial antioxidant
US$ 25.09
US$ 28.94
US$ 23.32
US$ 28.45
)
)
US$ 22.88
)
